Abpro Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABP research report →
Companyabpro.com
Abpro Holdings, Inc. , a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry.
- CEO
- Jin Wook Suk
- IPO
- 2022
- Employees
- 6
- HQ
- Woburn, MA, US
Price Chart
Valuation
- Market Cap
- $1.06M
- P/E
- -0.04
- P/S
- 2.99
- P/B
- -0.03
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -55.19%
- Op Margin
- -7950.82%
- Net Margin
- -7670.49%
- ROE
- 83.19%
- ROIC
- 93.80%
Growth & Income
- Revenue
- $183.00K · 50.00%
- Net Income
- $-7,232,000 · 38.22%
- EPS
- $-23.10 · 38.40%
- Op Income
- $-9,921,000
- FCF YoY
- -21.21%
Performance & Tape
- 52W High
- $18.03
- 52W Low
- $0.11
- 50D MA
- $2.72
- 200D MA
- $5.62
- Beta
- -0.00
- Avg Volume
- 1.72M
Get TickerSpark's AI analysis on ABP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ABP Coverage
We haven't published any research on ABP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ABP Report →